How Analysts Rated Revance Therapeutics, Inc

How Analysts Rated Revance Therapeutics, Inc

Therefore 90% are positive. The stock's 52-week range is $15.85 to $28.75, and its 3-month range is $23.35 to $37.20. They set an "outperform" rating and a $34.00 price target on the stock. Blackrock reported 2.15M shares stake. As per Thursday, July 20, the company rating was initiated by Cantor Fitzgerald.

Revance Therapeutics has one of the best ratings by the Street. Cantor Fitzgerald initiated the shares of RVNC in report on Thursday, July 20 with "Buy" rating. Revance Therapeutics had a negative net margin of 28,187.33% and a negative return on equity of 37.31%. The rating was initiated by Aegis Capital on Tuesday, November 29 with "Buy". The rating was maintained by Suntrust Robinson with "Buy" on Tuesday, June 14. The company was initiated on Monday, November 27 by Barclays Capital. The firm has "Buy" rating by SunTrust given on Thursday, November 2. A sell-side firm might have issued a buy report on the company. It now has negative earnings. Bank of America Corp DE increased its stake in shares of Revance Therapeutics by 29.5% in the first quarter.

Analysts await Sophiris Bio, Inc. (NASDAQ:RVNC). Essex Inv Mgmt Ltd Com reported 124,932 shares. The company's quarterly EPS surprised Wall Street by as much as 9% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.

Sabby Management Llc holds 0.05% of its portfolio in Sophiris Bio, Inc. for 357,792 shares. "Separately, CFO, CBO & Secretary SILVERNAIL LAUREN P Sell 10000 shares of the company at a price of $26.83 on 2017-11-07". The California-based Shelton Capital has invested 0.02% in Crown Castle International Corp. Barclays Capital initiated the shares of RVNC in report on Monday, November 27 with "Buy" rating. Franklin Resources Inc. boosted its position in shares of Revance Therapeutics by 13.1% in the second quarter. (NASDAQ:RVNC). Bnp Paribas Arbitrage reported 0% stake. They expect $-0.95 EPS, 0.00% or $0.00 from last year's $-0.95 per share. While in the same Quarter Previous year, the Actual EPS was $-0.95. Of those holders, 40 had increased positions amounting to 1.06 million shares, 39 had decreased positions amounting to 1.15 million shares, and 14 holders have a held position accounting for 25.22 million shares. Its down 0.11, from 1.42 in 2017Q1. Revance Therapeutics, Inc.'s now has a PEG ratio of - where as its P/E ratio is -.

More news: Cardinal Health, Inc. (CAH) Holdings Increased by Thompson Siegel & Walmsley LLC

Several hedge funds have recently added to or reduced their stakes in RVNC. (NASDAQ:RVNC). Schwab Charles Invest Mngmt reported 111,757 shares. Palisade Capital Limited Company Nj accumulated 675,982 shares. 600 were accumulated by Tower Research Cap Limited Company (Trc). Its up 0.64% from 19.11 million shares previously. Ameritas Investment Ptnrs Inc holds 1,969 shares or 0% of its portfolio.

In related news, CEO L Daniel Browne sold 7,600 shares of the company's stock in a transaction that occurred on Wednesday, September 20th. Creative Planning has invested 0% of its portfolio in Revance Therapeutics, Inc. State Of New Jersey Common Pension Fund D has invested 0% in Revance Therapeutics, Inc. (NASDAQ:RVNC). Great West Life Assurance Company Can holds 2,553 shares or 0% of its portfolio. The Massachusetts-based Panagora Asset Mngmt has invested 0% in Revance Therapeutics, Inc.

Guggenheim analyst Rohit Vanjani went through this process and came out today with a very upbeat and promising report on shares of Revance Therapeutics Inc (NASDAQ:RVNC). Prelude Cap Ltd Limited Liability Company holds 16,125 shares. Jennison Assoc Llc owns 378,400 shares. Tiaa Cref Invest Ltd Co, New York-based fund reported 59,509 shares. Moreover, Pnc Ser Group has 0% invested in SM Energy Company (NYSE:SM). The shares were sold at an average price of $24.94, for a total transaction of $189,544.00.

Revance Therapeutics, Inc. (RVNC) has the market capitalization of $1.05 Billion. It has outperformed by 3.70% the S&P500. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is now in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.

  • Elon Musk releases plan for tunnel system under Los Angeles

    Elon Musk releases plan for tunnel system under Los Angeles

    For more information visit The Boring Company website . "The Boring Company has filed an excavation permit application". Phase II is a huge expansion of the tunnel system and is simply a concept right now with no "finalized alignment".
    Injustice 2: NetherRealm Studios showcases Atom's abilities in new trailer

    Injustice 2: NetherRealm Studios showcases Atom's abilities in new trailer

    Fighter Pack 1 includes Red Hood, Starfire, and Sub-Zero, and Fighter Pack 2 features Black Manta, Raiden, and Hellboy. There are still no details of when the other characters will debut, but we will also see special trailers of them.
    Ronda Rousey Rumors: UFC Star 'Finalizing Details' to Sign WWE Contract

    Ronda Rousey Rumors: UFC Star 'Finalizing Details' to Sign WWE Contract

    That led to speculation that an official appearance is imminent, perhaps at Wrestlemania 34 in New Orleans on April 8. Ronda Rousey may finally be ready to test out a new career in professional wrestling.
  • Herndon Capital Management LLC Maintains Position in Valero Energy Corp (VLO)

    The oil and gas company reported $1.91 earnings per share for the quarter, beating the consensus estimate of $1.83 by $0.08. Investors will get a clear idea on how much they can earn per share on each of the outstanding shares of common stock.

    Taurus Asset Management LLC Maintains Stake in Jpmorgan Chase & Co (JPM)

    Analysts are also projecting an Average Revenue Estimate for JPMorgan Chase & $25.4 Million in the Current Quarter. Hennessy Advisors Inc. lifted its position in shares of J P Morgan Chase & Co by 6.3% in the first quarter. (NYSE:JPM).
    A snow-ice weather warning has been issued by Met Eireann

    A snow-ice weather warning has been issued by Met Eireann

    The warning is also in place for Mayo , Donegal and Kerry . "Thursday will be a cold, bright and windy day". Two separate weather warnings have been issued as Storm Caroline bears down on Ireland.
  • Oreo mystery flavor revealed … did you guess right?

    Oreo mystery flavor revealed … did you guess right?

    We've been wondering for two months when we would find out the true identity of the "Mystery Oreo" cookie flavor. The victor of the sweepstakes will be announced "on or around" December 11.

    Canadian National Railway (CNI) Earns News Impact Score of 0.18

    It is positive, as 62 investors sold AAPL shares while 1068 reduced holdings. 97 funds opened positions while 444 raised stakes. Callahan Advisors Llc decreased Brookfield Infra Ptnrs (NYSE:BIP) stake by 11,663 shares to 117,863 valued at $4.82M in 2017Q2.

    Institutional Investors Are Betting On Corcept Therapeutics Inc (NASDAQ:CORT)

    TheStreet upgraded Corcept Therapeutics from a "c+" rating to a "b" rating in a research report on Friday, March 10th. Piper Jaffray maintained Corcept Therapeutics Incorporated (NASDAQ: CORT ) on Friday, September 8 with "Buy" rating.
  • Price Target Analysis of Corning Inc. (NYSE:GLW)

    This continues to be an interesting story, and we look forward to updating it again soon on Corning Incorporated. The John G Ullman & Associates Inc holds 709,325 shares with $21.32M value, down from 734,037 last quarter.

    Commerzbank Aktiengesellschaft FI Boosts Holdings in Simon Property Group Inc (SPG)

    It has underperformed by 35.26% the S&P500.The move comes after 6 months positive chart setup for the $58.24 billion company. Its up 0.34, from 0.87 in 2017Q1. 628.79 million shares or 0.40% less from 631.34 million shares in 2017Q1 were reported.
    Ruben Kihuen: 'I'm Not Resigning'

    Ruben Kihuen: 'I'm Not Resigning'

    Democratic leaders - as well as House Speaker Paul Ryan, a Republican - also called for the resignation of longtime Rep. Ben Ray Lujan (N.M.), knew about the allegations a year ago and did nothing. "Sadly, this is not the case".